The injectable excess weight-decline medication Wegovy is available at New Metropolis Halstead Pharmacy on April 24, 2024 in Chicago, Illinois.
Scott Olson | Getty Photographs
Danish pharmaceutical giant Novo Nordisk, which became the most precious business in Europe very last yr because of to the blockbuster success of its pounds decline prescription drugs, on Thursday beat revenue estimates for the to start with quarter.
Web income rose 28% calendar year-on-calendar year to 25.4 billion Danish kroner ($3.65 billion), compared to analyst anticipations of 23.7 billion kroner, according to an LSEG poll.
Revenue of preferred fat decline drug Wegovy additional than doubled to 9.38 billion kroner.
In general North America sales rose 35%, as the company flagged that Wegovy experienced been approved in the U.S. in the initially quarter for cardiovascular threat reduction in persons with weight problems.
“We are pleased with the product sales growth in the initially a few months of 2024, pushed by enhanced demand from customers for our GLP-1-based mostly diabetic issues and obesity solutions,” CEO Lars Fruergaard Jørgensen explained in a statement.
Novo Nordisk lifted its outlook for 2024, nudging its revenue advancement outlook selection a person percentage position bigger, to 19% to 27% at continual trade costs. It also upped its functioning advancement forecast to 22% to 30% from a past forecast of 21% to 29%.
This is a breaking news tale and will be updated shortly.
